Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20170905 | 0.85 | ADRA1A (0.39) | ABL1SRCADRA1AKMT2AALDH1A1 | |
| SCHEMBL20743311 | 0.82 | KMT2A (0.33) | KMT2AL3MBTL1PRKCIPRMT6 | |
| SCHEMBL17788451 | 0.79 | ABL1 (0.38) | ABL1SRCCCNKCDK12ADRA1A | |
| SCHEMBL256684 | 0.79 | — | — | |
| SCHEMBL14292426 | 0.78 | KMT2A (0.46) | ABL1SRCKMT2AMEN1ALDH1A1 | |
| SCHEMBL26996077 | 0.78 | ADRA1A (0.39) | ADRA1AKMT2AL3MBTL1 | |
| SCHEMBL24425268 | 0.77 | UBE2M (0.33) | ADRA1AKMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL26693375 | 0.77 | HTR2C (0.47) | ALDH1A1MAPTHPGDNPC1L3MBTL1 | |
| SCHEMBL15660024 | 0.75 | — | — | |
| SCHEMBL10061627 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | ALKAHEST, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-3038466-B1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2516425-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8563539-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| CN-102884062-A | Aminopyrimidine kinase inhibitors | JASCO PHARMACEUTICALS LLC | 2013-01-16 | — | — | CN | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | ABL1 4356/4885SRC 4549/4885CCNK 4340/4885 |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | ABL1 233/4885SRC 195/4885CCNK 223/4885 |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | ABL1 1941/4885SRC 1765/4885CCNK 3011/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | ABL1 4273/4885SRC 3872/4885CCNK 856/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ABL1 2614/4885SRC 2884/4885CCNK 3060/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | ABL1 1978/4885SRC 2813/4885CCNK 3664/4885 |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | ABL1 210/4885SRC 178/4885CCNK 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.